Institutional Sign In

Go

GlaxoSmithKline Czech Republic - EBITDA Growth

GlaxoSmithKline CR`s EBITDA Growth reached 56.0 % in 2017. This is 202 % less than in the previous year.

$1.99

Buy EBITDA Growth data for GlaxoSmithKline Czech Republic.

$19.99

Buy all data for GlaxoSmithKline Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
Company Unit 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic % ... ... ... ... ...           50.4 -36.1 10.4 32.3 -15.0    
Bayer Czech Republic % ... ... ...               -0.531 -33.0 20.7 5.62 17.5    
GlaxoSmithKline Czech Republic % ... ... ...               27.4 -24.7 -19.4 -26.0 -0.486    
Merck Czech Republic % ... ...                 170 24.9 -41.2 8.97 78.8    
Novartis Czech Republic %                     3.11 13.4 2.54 57.5 15.7    
Pfizer Czech Republic % ... ...                 93.1 -79.0 160 -0.368 -35.9    
Roche Czech Republic % ... ... ...               -18.2 -1.49 60.6 -19.3 -21.0   ...
Sanofi-Aventis Czech Republic % ... ... ... ...             26.7 -10.9 22.2 -82.8 455    
Servier Czech Republic % ... ... ... ... ... ... ... ... ... ... ... ... 4.70 3.39 14.6    
Walmark % ... ... ...               14.2 -56.9 -15.1 70.2 -212